secwatch.observer — SEC 8-K summary
======================================

Issuer:     Carisma Therapeutics Inc. (CARM)
CIK:        0001485003
Form:       8-K
Filed at:   2024-12-09T23:59:59+00:00
Accession:  0001104659-24-126550
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 2.05, 5.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Carisma Therapeutics reduces workforce by 34%, terminates CFO, discontinues lead candidate CT-0525
--------------------------------------------------------------------------------

- Reduction of 23 employees (34% of workforce); expects ~$2.7M in one-time termination costs, substantially complete by Q1 2025.
- CFO Richard Morris terminated without cause effective Dec 31, 2024; entitled to 12 months base salary, target bonus, COBRA; retention option accelerated.
- Discontinues lead product CT-0525 (HER2 solid tumor) due to competitive landscape; final patient already enrolled in Phase 1.
- Revised plan focuses on in vivo mRNA/LNP CAR-M programs with Moderna, plus fibrosis, neurodegeneration, and other diseases; potential development of CT-1119.
- Company expects to appoint a consultant as principal financial and accounting officer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1485003/000110465924126550/0001104659-24-126550-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1485003/000110465924126550/tm2430483d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-126550

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer